Vascular tissue engineering: Towards the next generation vascular grafts

Yuji Naito, Toshiharu Shinoka, Daniel Duncan, Narutoshi Hibino, Daniel Solomon, Muriel Cleary, Animesh Rathore, Corey Fein, Spencer Church, Christopher Breuer

Research output: Contribution to journalReview articlepeer-review

Abstract

The application of tissue engineering technology to cardiovascular surgery holds great promise for improving outcomes in patients with cardiovascular diseases. Currently used synthetic vascular grafts have several limitations including thrombogenicity, increased risk of infection, and lack of growth potential. We have completed the first clinical trial evaluating the feasibility of using tissue engineered vascular grafts (TEVG) created by seeding autologous bone marrow-derived mononuclear cells (BM-MNC) onto biodegradable tubular scaffolds. Despite an excellent safety profile, data from the clinical trial suggest that the primary graft related complication of the TEVG is stenosis, affecting approximately 16% of grafts within the first seven years after implantation. Continued investigation into the cellular and molecular mechanisms underlying vascular neotissue formation will improve our basic understanding and provide insights that will enable the rationale design of second generation TEVG.

Original languageEnglish (US)
Pages (from-to)312-323
Number of pages12
JournalAdvanced Drug Delivery Reviews
Volume63
Issue number4
DOIs
StatePublished - Apr 30 2011
Externally publishedYes

Keywords

  • Bone marrow derived mononuclear cells
  • Extracellular matrix
  • Stem cells
  • Translational research
  • Vascular remodeling
  • Vascular tissue engineering

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Vascular tissue engineering: Towards the next generation vascular grafts'. Together they form a unique fingerprint.

Cite this